AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Antipsychotic Abilify (aripiprazole) approved for marketing in Europe.

Health & Medicine Week

| July 05, 2004 | COPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) and Otsuka Pharmaceutical Co., Ltd., announced that the European Commission has granted marketing authorization for Abilify (aripiprazole), an antipsychotic medication, for the treatment of schizophrenia.

"Receiving marketing approval for Abilify in 25 nations of the European Union marks a significant milestone for Abilify and for both companies, bringing an important medicine one step closer to the millions of people in Europe living with schizophrenia," said Peter R. Dolan, chairman and chief executive officer, Bristol-Myers Squibb.

"For patients with schizophrenia, Abilify has a unique pharmacology among the atypical antipsychotics and has demonstrated proven efficacy with a comprehensive tolerability and safety profile," said Tatsuo Higuchi, president & representative director, Otsuka Pharmaceutical Co., Ltd.

"We are proud to have discovered Abilify and now be able to offer this important therapy in the European Union for people in need of treatment options of schizophrenia. It will also give Otsuka an opportunity to strengthen the foundations to introduce more of Otsuka's innovative medicines to people in Europe," Higuchi said.

Otsuka Pharmaceutical Europe, Ltd., the London subsidiary of Otsuka Pharmaceutical Co., Ltd., holds the marketing authorization for Abilify in Europe. Bristol-Myers Squibb and Otsuka will co-promote Abilify in several European countries.

Schizophrenia is a chronic and persistent brain disorder and one of the most severe common mental illnesses. There are millions of people across Europe living with schizophrenia. It occurs in all cultures and affects approximately 1% of the population worldwide.

Schizophrenia interferes with a person's ability to think clearly, manage emotions, make decisions, and relate to others. This illness tends to manifest itself in early adulthood and is characterized by positive symptoms, such as hallucinations, delusions, and paranoia, as well as negative symptoms, such as social withdrawal and emotional flatness. While there is no cure for schizophrenia, it is a treatable illness.

Related articles from newspapers, magazines, journals, and more
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce...
Press release article from: PR Newswire February 7, 2006 700+ words
...Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced...newly available options of ABILIFY(R) (aripiprazole...solution (1 mg/mL). The ABILIFY 2 mg tablet equips physicians...difficulty swallowing tablets. ABILIFY is indicated for the treatment...
Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly...
Press release article from: PR Newswire August 17, 2006 700+ words
Provides Another ABILIFY Formulation Option for...Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY(R) DISCMELT(TM...antipsychotic medication ABILIFY(R) (aripiprazole...
Otsuka Pharmaceutical gains marketing approval of Abilify in the EU.
News wire article from: Asia Africa Intelligence Wire June 14, 2004 700+ words
...Business NewsBase - Pharma Japan) Otsuka Pharmaceutical has been granted marketing approval for its Abilify ariprazole atypical antipsychotic...and Germany during 2H 2004. Otsuka Pharmaceutical and Bristol-Myers Squibb will...
Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co Ltd announce availability...
News wire article from: Chemical Business Newsbase February 7, 2006 700+ words
...Myers Squibb Co and Otsuka Pharmaceutical Co Ltd announced two...available options of Abilify (aripiprazole...1 mg/ml). The Abilify 2 mg tablet equips...swallowing tablets. Abilify is indicated for the...Myers Squibb and Otsuka Pharmaceutical are collaborative...
Strong results for B-MS/Otsuka's Abilify.(Bristol-Myers Squibb Co.)(Otsuka...
Newspaper article from: Pharma Marketletter March 20, 2006 700+ words
...Squibb and Japan's Otsuka Pharmaceutical says that their co-devloped antipsychotic, Abilify (aripiprazole) demonstrated...schizophrenia treated with Abilify experienced significantly...more patients in the Abilify group than the SOC arm...
Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify to Garner 12% of the...
Press release article from: PR Newswire June 16, 2003 700+ words
...pharmaceutical and health care issues, forecasts Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify will garner 12% of the schizophrenia market...at Decision Resources. "The launch of Abilify, novel formulations of atypical antipsychotics...
Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify to garner 12% of the...
News wire article from: Asia Africa Intelligence Wire June 16, 2003 700+ words
...Release) Decision Resources Inc forecasts Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify will garner 12% of the schizophrenia market...analyst at Decision Resources. The launch of Abilify, novel formulations of atypical antipsychotics...
B-M S and Otsuka launch Abilify Discmelt.(Bristol-Myers Squibb and Otsuka...
Newspaper article from: Pharma Marketletter September 4, 2006 700+ words
...drugmaker Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have announced the launch of an orally disintegrating...version of their co-developed antipsychotic Abilify (arpiprazol), known as Abilify Discmelt. This follows the US Food and...
Abilify wins clearance.(RX: RETAIL PHARMACY: Branded Drugs)(FDA approves...
Magazine article from: Chain Drug Review March 17, 2008 700+ words
The FDA has approved Abilify for the treatment of acute bipolar I disorder in patients between ages 10 and 17. The product is marketed by Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Co.
Abilify approval.(RXs)(Bristol-Myers Squibb Co.)(Otsuka Pharmaceutical Company...
Magazine article from: Chain Drug Review January 22, 2007 700+ words
Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. have debuted Abilify injection. The product is indicated for adults with agitation associated with schizophrenia or bipolar mania.
For more facts and information, see all results

Source: HighBeam Research, Antipsychotic Abilify (aripiprazole) approved for marketing in Europe.

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA